Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy
- PMID: 21942620
- DOI: 10.3109/13697137.2011.586752
Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy
Abstract
Objective: Nasal administration gives a more acute but shorter rise in serum hormone levels than oral administration and may therefore have less effect on the fibroglandular tissue in the breasts. We studied the change in mammographic breast density after nasal vs. oral administration of postmenopausal hormone therapy (PHT).
Methods: We studied participants in a randomized, controlled trial on the impact of nasal vs. oral administration of PHT (combined 17β-estradiol plus norethisterone) for 1 year. Two radiologists classified mammographic density at baseline and after 1 year into four categories. Also, the percentage density was calculated by a computer-based method. The main outcome measure was the difference in the proportion of women with an increase in mammographic density category after 1 year between the nasal and oral groups. Also, the change in the percentage density was calculated.
Results: The study group comprised 112 healthy postmenopausal women (mean age 56 years), of whom 53 received oral and 59 intranasal PHT. An increase in mammographic density category after 1 year was seen in 20% of the women in the nasal group and in 34% of the oral group. This resulted in a non-significant difference in the proportion of women in whom mammographic breast density had increased by 214% (95% confidence interval (CI) 230% to 2.7%). The mean change in percentage density was 21.2% in the nasal group and + 1.2% in the oral group, yielding a 22.4% differential effect (95% CI 27.3% to 2.5%).
Conclusions: One year of nasal PHT gave a smaller, although not statistically significant, increase in mammographic density than oral PHT. Remaining issues are the relation between the route of administration of PHT and breast complaints and breast cancer risk.
Similar articles
-
Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.Climacteric. 2009 Jun;12(3):248-58. doi: 10.1080/13697130802638458. Climacteric. 2009. PMID: 19387884
-
HT update: spotlight on estradiol/norethindrone acetate combination therapy.Clin Interv Aging. 2008;3(1):9-16. doi: 10.2147/cia.s1663. Clin Interv Aging. 2008. PMID: 18488874 Free PMC article. Review.
-
Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.BJOG. 2008 May;115(6):773-9. doi: 10.1111/j.1471-0528.2008.01690.x. Epub 2008 Mar 19. BJOG. 2008. PMID: 18355366 Clinical Trial.
-
Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.Fertil Steril. 2007 Aug;88(2):383-9. doi: 10.1016/j.fertnstert.2006.11.142. Epub 2007 Jun 11. Fertil Steril. 2007. PMID: 17561009 Clinical Trial.
-
Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specificity and sensitivity of mammographic screening.Eur J Gynaecol Oncol. 2005;26(5):485-90. Eur J Gynaecol Oncol. 2005. PMID: 16285562 Review.
Cited by
-
Intranasal 17β-Estradiol Modulates Spatial Learning and Memory in a Rat Model of Surgical Menopause.Pharmaceutics. 2020 Dec 17;12(12):1225. doi: 10.3390/pharmaceutics12121225. Pharmaceutics. 2020. PMID: 33348722 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical